Edition:
India

Atreca Inc (BCEL.OQ)

BCEL.OQ on NASDAQ Stock Exchange Global Select Market

10.73USD
15 Oct 2019
Change (% chg)

$0.71 (+7.09%)
Prev Close
$10.02
Open
$10.07
Day's High
$11.05
Day's Low
$9.87
Volume
21,603
Avg. Vol
--
52-wk High
$23.65
52-wk Low
$9.87

Summary

Name Age Since Current Position

Tito Serafini

2016 President, Chief Executive Officer, Co-Founder, Director

Jonathan Woo

2016 Co-Founder, Senior Vice President - Finance and Strategy

Paulette Dillon

Co-Founder, Senior Vice President - Corporate Development

Daniel Emerling

Co-Founder, Vice President - Research

Susan Berland

60 Chief Financial Officer

Courtney Phillips

2019 General Counsel

Lisa Decker

2019 Chief Business Officer

David Lacey

66 Director

Biographies

Name Description

Tito Serafini

Dr. Tito A. Serafini is the Co-Founder, Chief Executive Officer, President and Director at Atreca Inc. Before founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory. Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University, and he performed postdoctoral research at the University of California, San Francisco.

Jonathan Woo

Dr. Jonathan Woo is the Co-Founder, Senior Vice President - Finance and Strategy at Atreca Inc. Prior to Atreca, he was an independent consultant to the biotechnology industry. Dr. Woo has held management positions of increasing responsibility at Bristol-Myers Squibb, Johnson & Johnson, Celera Genomics, and Avidia. Before entering the biotechnology industry, Dr. Woo was a management consultant with Mitchell Madison Group. Dr. Woo received a BA in biochemistry from the University of California, Berkeley, a PhD in chemistry from Northwestern University, and he performed postdoctoral research at Memorial Sloan-Kettering Cancer Center.

Paulette Dillon

Mrs. Paulette A. Dillon is Co-Founder, Senior Vice President - Corporate Development of the company. Prior to her role at Atreca, Mrs. Dillon served sequentially as the Chief Business Officer of Nuon Therapeutics, Anacor, Avidia, and Celera Genomics, and held previous positions including Vice President at Exelixis and Hoffmann-La Roche where she led business development and strategic marketing for the Inflammatory Diseases Unit, and senior marketing and sales management positions at Syntex. She has led corporate/business development, commercial operations, global marketing and multiple product launches for start-up to large pharmaceutical and biotechnology companies. Mrs. Dillon received a BS from the University of California, Los Angeles.

Daniel Emerling

Dr. Daniel Emerling is the Co-Founder and Vice President - Research at Atreca Inc. Prior to founding Atreca, he was Senior Director of Pharmacology at Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Emerling was Senior Director of Preclinical Pharmacology at Renovis (and then at Evotec, its acquirer), which he joined as its first scientist. Dr. Emerling received a BA in biochemistry from the University of California, Berkeley, and a PhD in neurobiology from the Massachusetts Institute of Technology, and he performed postdoctoral research at the University of California, Berkeley.

Susan Berland

Ms. Susan D. Berland is the Chief Financial Officer of the Company. Susan Berland has over 20 years of experience in diverse areas of financial management and business transactions. Her senior management experience has included the position of Chief Financial Officer for Mendel Biotechnology and Poniard Pharmaceuticals. Earlier in her career she was Director in Monsanto’s corporate M&A group, and she subsequently led that company’s financial planning function through their merger with Pharmacia & Upjohn. She has worked in a variety of industries including life sciences (pharmaceuticals, molecular diagnostics, and medical devices), agriculture (seed operations, biotechnology, and crop protection), and telecommunications. Ms. Berland holds MBA and BBA degrees from the University of Wisconsin – Milwaukee.

Courtney Phillips

Ms. Courtney J. Phillips is General Counsel of the Company. Ms. Phillips will lead Atreca's legal, compliance and intellectual property functions. She is a seasoned attorney with deep experience leading corporate and transactional matters at public biopharmaceutical companies, including corporate governance, compliance, contracting, securities law matters and SEC reporting, financings, and employment law matters. Prior to joining Atreca, Ms. Phillips was the Vice President of Corporate Law at Global Blood Therapeutics, where she led a broad range of legal activities. Prior to joining Global Blood Therapeutics, she was Senior Counsel and then Vice President and Associate General Counsel at Relypsa where she led a wide variety of legal matters as the company transitioned from IPO through commercialization of its first product and acquisition by Galenica. Prior to joining Relypsa, she was Corporate Counsel at Affymax. Earlier in her career, Ms. Phillips was a corporate attorney at the law firms of Morrison Foerster LLP and Reed Smith LLP, where she represented public and private life science and technology companies in mergers and acquisitions, securities law matters and equity financings. Ms. Phillips holds a J.D. from Georgetown University Law Center and a B.A. from the University of California, Berkeley.

Lisa Decker

Dr. Lisa L. Decker, Ph.D. is Chief Business Officer of the Company. As Chief Business Officer, Dr. Decker will lead Atreca's corporate development function, including its strategic partnering initiatives and alliance management. As a senior executive with experience in negotiating and executing strategic partnerships in all areas and stages of biopharmaceutical development, Dr. Decker is ideally suited for this role. Prior to joining Atreca, she served as the Vice President of Business Development at Nektar Therapeutics. In that role, she was responsible for all partnering activities, including most recently leading negotiations for their broad-based clinical collaborations with Bristol Meyers Squibb on NKTR-214. Dr. Decker also executed multiple additional research collaborations over more than ten years at Nektar with partners such as Pfizer, Eli Lilly, Takeda, and Gilead. Prior to joining Nektar, Dr. Decker was the Associate Director of Technology Licensing at the University of Massachusetts Medical School where she led the partnering and intellectual property strategy efforts for a diverse array of early stage technologies, including the University's Nobel Prize winning RNAi portfolio. Dr. Decker holds a Ph.D. in Immunology from Tufts University School of Medicine and conducted her postdoctoral training at Harvard Medical School.

David Lacey

Dr. David L. Lacey is the Director of the Company. Dr. Lacey, formerly Senior Vice President of Discovery Research at Amgen, possesses over 20 years of scientific and senior leadership experience within the life sciences, focused on creating new medicines to make a difference in the lives of patients worldwide. During his tenure at Amgen Dr. Lacey lead an organization of more than 1200 scientists across a portfolio of drug discovery and development projects in the therapeutic areas of hematology/oncology, inflammation, metabolic disorders, and neuroscience. Prior to joining Amgen, he was on the faculty at Washington University in St. Louis, MO. Dr. Lacey currently serves as a Board member for Nurix N.V. and Inbiomotion SL, and acts as an advisor to a number of academic institutions, biotechnology, and venture capital firms. Dr. Lacey received a bachelor’s degree in biology and an MD degree from the University of Colorado.